Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Modeling substance abuse for applications in proteomics.
PMID 20058165 · PMC3272758 · Methods in molecular biology (Clifton, N.J.) · 2009 · 8 claims · 5 setups
The intravenous self-administration paradigm models the reinforcing effects of abused drugs and allows biochemical alterations to be correlated with drug reinforcement.
-
Has reproduction · 92
Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes.
PMID 28446242 · PMC5406893 · Genome medicine · 2017 · 8 claims · 7 setups
Application of GFRN pathway signatures to breast tumor gene expression data identifies two discrete phenotypes: a 'survival phenotype' (concordant activation of HER2, IGF1R, AKT) and a 'growth phenotype' (concordant activation of EGFR, KRAS(G12V), RAF1, BAD)
-
Full-text index only
Utilization of genomic signatures to identify phenotype-specific drugs.
PMID 19714244 · PMC2729377 · PloS one · 2009 · 8 claims · 8 setups
A RAS pathway gene expression signature applied to NCI-60 cells identifies compounds selectively active against RAS-activated cells, including the MEK inhibitor Hypothemycin
-
Full-text index only
Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary.
PMID 19014506 · PMC2615745 · Theoretical biology & medical modelling · 2008 · 8 claims · 6 setups
A biphasic treatment approach—acute DA receptor blocking followed by long-term DA release/activation at the NAc—is needed to treat RDS without inducing abnormal mood or craving.
-
Full-text index only
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
PMID 18676830 · PMC2680495 · Cancer research · 2008 · 8 claims · 5 setups
PIK3CA mutations are more common in hormone receptor-positive and HER2-positive tumors than in basal-like breast cancers
-
Full-text index only
The flexible pocketome engine for structural chemogenomics.
PMID 19727619 · PMC2975493 · Methods in molecular biology (Clifton, N.J.) · 2009 · 8 claims · 8 setups
A comprehensive structural Pocketome combined with ensemble docking enables de novo, structure-based prediction of ligand binding poses and activities for new proteins and new chemical scaffolds.
-
Has reproduction · 73
FRMD8 inhibits tumor metastasis in BRCA1-associated TNBC by negatively regulating tmTNF-α.
PMID 40619383 · PMC12229025 · Cellular & molecular biology letters · 2025 · 8 claims · 8 setups
Low FRMD8 expression in BRCA1-mutant breast cancer cells significantly enhances metastatic potential to various organs
-
Has reproduction · 85
An integrated single-cell and spatial proteotranscriptomics atlas of fibroblast-driven immunoregulation within the human adult oral cavity.
PMID 42147490 · PMC13179517 · Cell press blue · 2026 · 8 claims · 8 setups
Fibroblasts act as central regulators of structural immunity in the human oral cavity, forming peri-epithelial hubs enriched in effector cytokines
-
Full-text index only
The application of genomics to emerging zoonotic viral diseases.
PMID 19855817 · PMC2734983 · PLoS pathogens · 2009 · 8 claims · 8 setups
High-throughput sequencing, mRNA expression profiling, and SNP microarray analysis enable rapid identification and genomic characterization of emerging zoonotic pathogens and host responses to them.
-
Full-text index only
Unveiling the NEFH+ malignant cell subtype: Insights from single-cell RNA sequencing in prostate cancer progression and tumor microenvironment interactions.
PMID 39759507 · PMC11695424 · Frontiers in immunology · 2024 · 8 claims · 8 setups
A malignant cell subtype in PCa with high expression of NEFH was identified, located at the differentiation terminal, showing higher malignancy and association with advanced tumor lesions.
-
Full-text index only
Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients.
PMID 18366776 · PMC2311324 · BMC neurology · 2008 · 6 claims · 3 setups
ACE I/D genotype and allele distributions do not differ significantly between migraine patients and controls
-
Full-text index only
Protein microarray technology.
PMID 17126887 · PMC1828913 · Mechanisms of ageing and development · 2007 · 8 claims · 8 setups
Protein microarrays enable high-throughput characterization of protein biochemical activities across an entire proteome in a single experiment
-
Has reproduction · 71
Targeted and personalized immunotherapy in lung adenocarcinoma: single-cell RNA sequencing of MAFF+ tumor cells and the therapeutic potential of FOS.
PMID 40936936 · PMC12420628 · Frontiers in immunology · 2025 · 7 claims · 8 setups
A highly stem-like C0 MAFF+ tumor cell subtype dominates invasive LUAD, producing chemokines and activating lipid metabolism
-
Full-text index only
Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy.
PMID 15601541 · PMC3525069 · Human genomics · 2004 · 8 claims · 6 setups
DNA microarray gene expression profiling generates robust molecular classifications for many tumour types (brain, breast, colon, gastric, kidney, leukaemia, lymphoma, lung, melanoma, ovary, prostate, etc.)
-
Full-text index only
siRNA screen of the human signaling proteome identifies the PtdIns(3,4,5)P3-mTOR signaling pathway as a primary regulator of transferrin uptake.
PMID 17640392 · PMC2323231 · Genome biology · 2007 · 8 claims · 8 setups
The PtdIns(3,4,5)P3-mTOR signaling pathway is a primary positive regulator of transferrin uptake.
-
Full-text index only
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.
PMID 18371219 · PMC2397526 · Breast cancer research : BCR · 2008 · 7 claims · 4 setups
PIK3CA mutations are not associated with altered sensitivity to preoperative anthracycline-based or taxane-based chemotherapy in ER-positive and ER-negative breast tumors